Latest Clinical News

Cost effective clinical trials are being provided in various countries in Asia and Eastern Europe, the main reason for this is to increase the growth and revenue for this specialist industry, This has had an impact on many Pharmaceutical and Bio-tech companies who are now outsourcing the clinical trial research to these countries.A large amount of specialists in the pharmaceutical industry have recognised this trend and are making use of this cost effective service offered abroad due to the large amount willing volunteers and also due to the international increase in demand for healthcare products.

The conduct of Clinical Trials has become cost effective in these countries.

Organisations such as pharmaceutical and biotechnology companies, as well as contract service providers, are faced with some challenging ethical business issues as sales and research continues to boom in these regions. Due to a lack in logistical and institutional capacity, many of these countries are faced with situations which lead to government representatives and business leaders accepting bribes or becoming involved in other corrupt acts with the aim of securing approval to conduct a certain clinical trial, or acquiring the materials to conduct these studies.

The Corruptions Perceptions Index, monitored by Transparency International (a not-for-profit organisation based in Berlin), affords a basis for which the risk of corruption can be approximated.The index is intended to rate countries based on the opinions of state analysts and business executives.India was ranked 85th , China 72nd and Brazil 18th out of 180 countries where the country ranked the lowest would be considered to be the least corrupt.

Pharmaceutical and Biotechnology organisations need to consider this before looking to outsource their studies in other countries. They need to be fully aware of the ethical violations that there CRO partners may encounter. If these organisations are ignorant towards this, the clinical trial may in turn be jeopardised or the trial outcome report could be made invalid if the CRO carrying out the study have breeched any ethics violations that may be in place. This could be detrimental for the organisation’s reputation, and could hinder any business in that country for the future.

Nicky Hargreaves has over 24 years in R&D, manufacturing, quality and regulatory affairs.”Trusted UK based Clinical Research organisations or pharmacology companies who provide  professional clinical trials (providing the statistical analysis, Clinical Data Management and the clinical research) that assists with the development of new drug entities are known to be the top resource.” Says Nicky; who is a microbiologist by training and has managed projects in numerous divisions, including pharmaceutical, medicinal, OTC, oral healthcare and animal healthcare.

* Before taking any medical advise you should consult your doctor. *